Wide spectrum of symptomatic treatment in Lambert-Eaton myasthenic syndrome

Annals of the New York Academy of Sciences

Volumn 841, Issue , 1998, Pages 827-831

  Oh, Shin J ^a   Kim, Dae S ^a   Kwon, Kee H ^a   Tseng, Anna ^a   Mussell, Holly ^a   Claussen, Gwen C ^a  

^a The University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIAMINOPYRIDINE; GUANIDINE; PYRIDOSTIGMINE;

ABDOMINAL PAIN; ADULT; CLINICAL ARTICLE; CONFERENCE PAPER; DIARRHEA; DRUG EFFICACY; EATON LAMBERT SYNDROME; ELECTROPHYSIOLOGY; FEMALE; HUMAN; INSOMNIA; LUNG SMALL CELL CANCER; MALE; MUSCLE FATIGUE; MUSCLE WEAKNESS; NAUSEA; SIDE EFFECT; SYNCOPE; VOMITING;

EID: 0031879612     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1998.tb11025.x     Document Type: Conference Paper

References (6)

1. NILSSON, L. H. & R. I. JOHANSSON. 1993. Practical aspect of 3,4-diaminopyridine treatment of the Lambert-Eaton myasthenic syndrome. Acta Neurol. Scand. 88: 136-140.
2. MCEVOY, K. M., A. J. WINDERBANK, J. R. DAUBE & P. A. LOW. 1989. 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. N. Engl. J. Med. 321: 1567-1571.
3. OH, S. J., D. S. KIM, T. C. HEAD & G. C. CLAUSSEN. 1997. Low-dose guanidine and pyridostigmine: relatively safe and effective long-term symptomatic therapy in Lambert-Eaton myasthenic syndrome. Muscle Nerve 20: 1146-1152.
4. LAMBERT, E. H. 1966. Defects of neuromuscular transmission in syndromes other than myasthenia gravis. Ann. N.Y. Acad. Sci. 135: 367-384.
5. OH, S. J. & K. W. KIM. 1973. Guanidine hydrochloride in the Eaton-Lambert syndrome. Neurology 23: 1084-1090.
6. HENRIKSSON, K. G., O. NILSSON, I. ROSEN & H. H. SCHILLER. 1977. Clinical, neurophysiological, and morphological findings in Eaton-Lambert syndrome. Acta Neurol. Scand. 56: 117-140.